NEW YORK--(BUSINESS WIRE)--Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Isabel Kurth, Ph.D., Vice President of Research at Rgenix, will present an abstract about Rgenix’s RGX-019 program at the 2019 American Association for Cancer Research Annual Meeting. The meeting is scheduled to take place Friday, March 29 through Wednesday, April 3 in Atlanta.
The details of Rgenix’s presentation are as follows:
AACR Annual Meeting 2019
|Date:||April 3, 2019|
|Time:||8:00 A.M. - 12:00 P.M. EST|
|Description:||Abstract LB-277/23, “Characterization of the anti-cancer and immunologic activity of RGX-019, a novel pre-clinical stage humanized monoclonal antibody targeting the MERTK receptor”|
|Location:||Section 40, Georgia World Congress Center, 285 Andrew Young International Blvd|
|NW, Atlanta, GA 30313|
Dr. Kurth will present data from pre-clinical research of RGX-019, a novel pre-clinical stage humanized monoclonal antibody targeting the MERTK receptor.
Rgenix, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. Rgenix identifies novel cancer targets using a microRNA based target discovery platform originally developed by Rgenix’s scientific co-founders at The Rockefeller University and now exclusively licensed to Rgenix. The company brings together distinguished scientific founders, a seasoned Board, and a leadership team comprised of experienced drug developers. The company is funded by leading biotechnology investors, including Novo Holdings A/S, Sofinnova Partners, Lepu Holdings Limited, Oceanpine Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture Investments,LLC, and the Partnership Fund for New York City. For more information, please visit www.rgenix.com.
RGX-019 is an investigational drug candidate and a humanized monoclonal antibody that targets MERTK being developed by Rgenix for the treatment of advanced cancer. Rgenix in-licensed RGX-019 related antibody intellectual property from Rockefeller University as part of a world-wide exclusive licensing agreement.
MERTK is a receptor tyrosine kinase of the TAM family and is over-expressed in several human cancers. The MERTK pathway drives cancer progression, tumor angiogenesis, and innate immune suppression. Targeting MERTK inhibits the growth of MERTK-expressing cancer cells and induces an M1 pro-inflammatory cytokine expression profile in tumor-associated macrophages. Rgenix has initiated IND-enabling studies of RGX-019.